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What is already known about this topic? 
 Treatment with intensive insulin regimens [multiple daily injections (MDI) and 
continuous subcutaneous insulin infusion (CSII)] is associated with superior 
glycaemic control in patients with type I diabetes (TID) 
 Meta-analyses and economic evaluations reporting CSII to be a cost effective 
treatment are based on small randomised controlled trials (RCTs) and observational 
data and subject to considerable modelling. 
 Results of a cluster randomised trial in adults with type 1 diabetes (REPOSE) in which 
both groups received similar structured education did not demonstrate support for a 
policy of providing insulin pumps over multiple daily injections. 
 An adequately powered RCT and economic evaluation was required to compare the 
effectiveness, safety and cost utility of CSII with MDI in children in the year following 
diagnosis of TID. 
What does this study add? 
 Glycaemic control was suboptimal in both treatment arms at the end of the first year 
of TID 
 Treatment with CSII is not more clinically effective than treatment with MDI in 
infants, children and young people in the first year following diagnosis of TID 
 Treatment with CSII as a standalone treatment was not cost effective in infants, 
children and young people in the first year following diagnosis of TID 
 Parents of children treated with CSII, but not children, reported superior quality of 
life for their children compared to parents of participants treated with MDI.  
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ABSTRACT 
OBJECTIVES  
To compare the efficacy, safety and cost utility of CSII with MDI during the first year following 
diagnosis of TID in paediatric patients.   
DESIGN  
Pragmatic, open, multicentre, parallel group, randomised, controlled trial.  
SETTING 
15 paediatric National Health Service (NHS) diabetes services in England and Wales.  
PARTICIPANTS 
Patients between 7 months and 15 years of age, newly diagnosed with TID were eligible to 
participate. Patients with a sibling with TID, those who took medications or had additional diagnoses 
that may influence glycaemic control were ineligible.  
INTERVENTIONS 
Participants were randomised, stratified by age and centre, to start treatment with CSII or MDI 
within 14 days of diagnosis. Starting doses of aspart (CSII and MDI) and glargine or detemir (MDI) 
were calculated according to weight and age, and titrated according to blood glucose measurements 
according to local clinical practice. 
MAIN OUTCOME MEASURES 
Primary outcome :glycaemic control (HbA1c) at 12 months. Secondary outcomes: percentage of 
patients in each treatment arm with HbA1c within the national target range; incidence of severe 
hypoglycaemia  and diabetic ketoacidosis (DKA); change in height and body mass index (BMI) 
standard deviation score (SDS); insulin requirements (units/kg/day); partial remission rate (insulin 
dose adjusted HbA1c (IDAAC) < 9), PedsQL score; cost-utility based on the incremental cost per 
Quality-Adjusted Life-Year (QALY) gained and an NHS costing perspective.   
RESULTS 
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294 participants were randomised  and 293 included in intention to treat analyses (CSI=144 and 
MDI=149). At 12 months mean HbA1c was comparable with clinically unimportant differences : 
60.9mmol/mol in CSII participants and: 58.5mmol/mol in MDI participants, mean difference (CSII-
MDI) 2.4mmol/mol (95% -0.4 to 5.3), p=0.09.  Achievement of HbA1c <58mmol/mol was low: 66 
(46%) of 143 CSII participants and 78 (55%) of 142 MDI participants, RR 0.84 95%CI (0.67 to 1.06).  
Incidence of severe hypoglycaemia and DKA were low in both groups. Sixty-eight adverse events 
(AEs) (14 serious) were reported during CSII treatment and 25 AEs (8 serious) during MDI treatment. 
Parents, but not children, reported superior PedsQL scores for those treated with CSII. CSII was more 
expensive than MDI by £1,863 (95% CI £1,620 to £2,137) per patient with no additional QALY gains, -
0.006 (95% CI -0.031 to 0.018).  
CONCLUSION 
During the first year of TID no clinical benefit of CSII over MDI was identified in the UK setting and 
treatment with either regimen was suboptimal in achieving HbA1c thresholds. CSII was not cost-
effective.  
TRIAL REGISTRATION 
International Standard Randomised Controlled Trial Number registry (ISRCTN29255275) and 
European clinical trials database (EudraCT number: 2010-023792-25).  
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Type I diabetes (TID) is  a common, chronic disease of childhood, affecting approximately 26,000 
infants, children and young people in the United Kingdom.1 Treatment requires administration of 
subcutaneous insulin in doses calculated according to carbohydrate consumption, physical activity 
and blood glucose measurements. During childhood and adolescence, poor glycaemic control is 
associated with impaired memory,2 poorer cognitive outcomes,3 an increased risk of depression4 and 
poor growth.5  In the longer term, vascular complications lead to blindness, renal failure, premature 
heart disease, stroke and amputation.6  The risk of developing complications is related to glycaemic 
control, and is lower in patients treated with intensive insulin treatment regimens: multiple daily 
injections (MDI) and continuous subcutaneous insulin infusions (CSII).7 There is no cure for TID so 
optimal treatment is essential to enable the best possible quality of life (QoL) and effective use of 
healthcare resources while minimising the risk of complications. 
A meta-analysis of six randomised controlled trials (RCTs) involving 165 children reported a modest 
benefit of CSII treatment on glycaemic control (HbA1c -0.24%, 95% CI -0.41 to -0.07)8 albeit below 
the threshold associated with better clinical outcomes (0.5%),7 but no difference in the risk of severe 
hypoglycaemia or diabetic ketoacidosis (DKA).8   However, key limitations need to be considered 
when interpreting these results. First, in five of the included RCTs  the observation period was 
insufficient (≤ seven months) for the effects of treatment fatigue to be observed, and may not have 
been long enough for patients to become fully competent in the use of CSII.  Second, the use of 
isophane insulin in the MDI arm of five of the studies included, limits the generalisability of the 
results to modern regimens using long acting insulin analogues. Third, five of the six RCTs 
randomised patients with established TID treated with MDI to continue MDI treatment or change to 
CSII. This introduces selection bias: patients in whom MDI treatment is satisfactory are less likely to 
be invited or to consent to participate than those in whom treatment is inadequate. A more recent 
study in which MDI treated patients with established TID, in whom treatment was inadequate, were 
randomised to either continued MDI treatment for six months or to change to CSII, reported 
beneficial effects of CSII on QoL, but no effect on HbA1c.9 
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In a small RCT of newly diagnosed patients observed for two years, there was no difference in 
glycaemic control or adverse events (AEs) between treatment arms.10 Finally, at the start of CSII 
therapy there is a period of intense education and frequent contact with diabetes health care 
professionals, which may influence glycaemic control independently of CSII treatment in those with 
established diabetes. When adult patients with TID and poor glycaemic control were randomised to 
treatment with CSII or MDI and given equivalent education in the REPOSE study, no additional 
benefit from CSII was identified.  11 
Observational studies of national paediatric databases from the United States, United Kingdom, 
Germany and Austria report an association between CSII treatment and superior glycaemic 
control12,13 with only a modest effect.  CSII use is lower in patients from ethnic minorities and those 
with greatest socioeconomic deprivation.14-16 Given that glycaemic control and severe 
hypoglycaemia are independently related to ethnicity and deprivation,14-16 there is a risk of bias, 
inherent to observational data, in estimates of the effect of CSII in these studies.  
The cost of T1D to the NHS is significant, with estimates ranging from £1bn to £1.8bn a year 17,18 and 
expected to be nearly 2% of total NHS expenditure over the next two decades.17A cost effectiveness 
analysis form the REPOSE study concluded that routine use of CSII in adults, without an immediate 
clinical need, would not be cost effective.19  The economic evidence, which indicates more expensive 
treatment with CSII to be cost-effective in paediatrics,20,21  relies on data from these limited trials and 
extensive modelling. Use of CSII in paediatric practice increased from 14% of patients in 2011 to 28% 
in 2015-2016.1 The widespread adoption of CSII, with little evidence of treatment superiority 
compared to MDI, requires an adequately powered RCT, designed to address areas of bias inherent 
in previous studies.  We therefore conducted the SCIPI trial (SubCutaneous Insulin: Pumps or 
Injections?), in which we recruited paediatric patients newly diagnosed with TID, and compared 
outcomes after one year.  
METHODS 
Patient and Public Involvement 
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Study design, delivery and data interpretation was undertaken in close discussion with patients and 
their families. Young people were consulted on the design of the study including impact of 
participation, outcome measures and study materials. Parents of children and young people with TID 
were members of the Trial Management Committee and Trial Steering Committee and advised on 
recruitment strategy.   Study results and their significance to patients and their families were 
discussed in detail with parent contributors.  
Trial Design 
The study protocol has been previously published.22 In brief, we conducted a pragmatic, multicentre, 
open label, parallel group, randomising participants to CSII or MDI  to compare efficacy, safety and 
cost utility. The study was conducted in paediatric diabetes services experienced in use of CSII, in 
nine university and six local hospitals within the NHS in England and Wales. The study protocol 
(supplementary appendix) was approved by the Liverpool East Research Ethics Committee, UK, 
reference 10/H1002/80.  
An internal pilot tested study feasibility, and the standard deviation used to inform the power 
calculation. A consent rate of ≥50%, with no differences likely to be of clinical significance in 
demographic criteria for age, ethnicity, gender and deprivation score between those that consented 
and declined to participate was required to proceed to the full study.  
Study sites were selected on the basis of the availability of a core set of experienced staff who had 
completed a recognised insulin pump therapy course and had their competencies assessed and 
authorised. 
Participants 
Patients between 7 months and 15 years of age, newly diagnosed with TID were eligible to 
participate.   Patients with any of the following characteristics were ineligible: previous treatment for 
TID, haemoglobinopathy, co-existing conditions or treatment likely to affect glycaemic control, 
psychological or psychiatric disorder, an allergy to a component of insulin aspart /determir (Novo 
Nordisk, Gatwick, UK) or insulin glargine (Sanofi, Guildford, UK), a sibling with TID.  Patients with 
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thyroid disease or coeliac disease were eligible if thyroid hormone concentrations or coeliac 
antibodies demonstrated good adherence to treatment.  
Patients and carers were given written, age appropriate, study information at diagnosis of TID, 
supplemented by a video presented by participants and parents from February 2014.  Written, 
informed consent, and where appropriate assent, was obtained from carers and participants.   
Randomisation 
Patients were randomised to treatment with CSII or MDI using 1:1 web-based block randomisation 
stratified by age (7 months to <5 years, 5 years to <12 years, ≥12 years) and treating centre.     
Participants were recruited by members of their local diabetes service and research nurses trained in 
the recruitment of paediatric patients. Parents and carers, and when appropriate patients, were 
invited to share reasons for declining to participate. 
Procedures 
The following baseline data, from the time of diagnosis of TID, were collected: blood pH, blood 
glucose, HbA1c, thyroid function tests, anti-islet cell and anti-GAD antibodies, tissue 
transglutaminase or other antibody test for coeliac disease measured per local practice prior to 
consent and did not form part of the study protocol. All participants completed a structured 
educational program, which covered the syllabus outlined by the International Society for Paediatric 
and Adolescent Diabetes.23 This included type 1 diabetes, the use and administration of insulin, 
hyperglycaemia and correction of dose, hypoglycaemia symptoms and treatment, exercise, sick day 
rules, carbohydrate counting, the benefits of maintaining optimal glycaemic control for long-term 
health and blood glucose monitoring.  The number of education sessions was recorded to ensure 
parity across treatment arms. All participants received training on the use of MDI regimen and the 
Expert glucometer with participants  randomised to CSII receiving additional training in the use of 
CSII. All advanced pump features were taught, used and regularly reviewed. 
Randomised treatment started within 14 days of diagnosis of TID.  Baseline height and weight were 
documented on the day randomised treatment started. Participants randomised to CSII were treated 
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with insulin aspart, and those randomised to MDI with the short acting insulin analogue insulin 
aspart and a long acting insulin analogue, either insulin glargine or detemir, according to local clinical 
practice. Insulin doses were calculated according to weight and age (see study protocol, 
supplementary appendix), and titrated against blood glucose readings according to local protocols. 
Participants in both treatment arms used a glucometer which included a ‘bolus wizard’, which 
calculated insulin doses according to blood glucose readings and carbohydrate consumption. 
Study visits coincided with clinic appointments at three, six, nine and twelve months. At each visit 
the following data were collected: HbA1c, AEs, height, weight, concomitant medications and insulin 
usage from prescriptions, glucometer and insulin pump downloads (CSII) and patient kept records 
(MDI). Participants and carers documented home episodes of severe hypoglycaemia24 and DKA in a 
diary. Treatment diaries and telephone logs were assessed at each study visit for any treatment 
related AEs and related serious AEs (SAEs).25 
In addition to self-reporting, local hospital databases were interrogated at each clinical assessment 
to ascertain whether the participant had been treated for a related SAE in the preceding three 
months. AEs were classified according to relationship with the injection device, glucometer, insulin, 
errors in insulin administration or incidental illness.   
The Health Utilities Index (HUI) questionnaire26 was administered at baseline and each study visit, 
and the diabetes module of PedsQL27was completed at six and twelve months. 
Resource use was measured using questionnaires and by accessing prescription records and 
electronic patient-linked information costing systems. These included the purchase of pumps or MDI 
injection devices and associated consumables, insulins, and contact with healthcare services 
including family doctors, school nurses, hospital inpatient, outpatient, and Emergency Department 
attendances.   
Data were collected on paper-based case report forms and questionnaires and entered centrally at 
the clinical trials unit into MACRO (InferMed Ltd, London, UK), a compliant clinical data management 
system. Bespoke software was developed to receive data downloaded from glucometers and pumps. 
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Outcome Measures 
The primary outcome measure was HbA1c twelve months following diagnosis of TID. Blood samples 
were analysed locally and centrally at Alder Hey Children’s Hospital, Liverpool using the Siemens DCA 
Vantage HbA1c analyser. Within batch precision is <6% and between batch precision is <8%. A limits 
of agreement analysis was undertaken for measurements made in different laboratories and by 
‘point of care’ (POC) methods.28 Sensitivity analyses were performed using samples analysed 
centrally only, POC only and POC in preference to central if both were available. Secondary outcome 
measures were: the percentage of patients in each treatment arm with HbA1c within the national 
target range;29 incidence of severe hypoglycaemia (hypoglycaemia associated with altered 
consciousness), and DKA; change in height and body mass index (BMI) standard deviation score 
(SDS); insulin requirements (units/kg/day); partial remission rate defined as insulin dose adjusted 
HbA1c (IDAAC) < 9( HbA1c (%) + [4 x insulin dose (U/Kg/24h)])30, PedsQL score; cost-utility based on the 
incremental cost per Quality-Adjusted Life-Year (QALY) gained.   
Statistical Analysis 
SCIPI was designed as a superiority trial assuming a null hypothesis of no difference. To detect a 
difference in means of 0.5% (or 5.46 mmol/mol conversion),31 the minimum difference generally 
considered to be clinically meaningful,7  with common standard deviation of 1.50 using a two group 
t-test with a 0.05 two-sided significance level, 286 participants (143 per group) were required to 
achieve 80% power. To allow for 10% loss to follow up, the recruitment target was increased to 316 
participants (158 per group).   
At the time of designing the trial the association between HbA1c at diagnosis and longer term 
outcomes was speculative. At baseline HbA1c, reflects blood glucose in the previous three months 
when the child is untreated and including baseline values may add to variation therefore  the sample 
size calculation was based on HbA1c at 12 months follow up.32  Two exploratory analyses were 
considered to include HbA1c measured at baseline as a continuous explanatory variable. 
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The ITT principle was used for the primary analysis such that all randomised participants in whom 
the outcome was observed were included in the group to which they were randomly allocated. A 
0.05 level of statistical significance and 95% confidence intervals are used throughout. The statistical 
and health economic analysis plans33 were developed prior to analysis and are available as 
supplementary material.  Analyses were conducted using SAS software (version 9.2; SAS Institute 
Inc., Cary, NC, USA) or Stata (version 13; StataCorp LLC, College Station, TX, USA). Independent 
statisticians from within the clinical trials unit produced and monitored the randomisation lists, 
statistical analysis plan 33 and undertook quality control via independent programming for the 
primary outcome and safety analyses. Blinding of the trial statistician was not possible, however 
inclusion of each participant within each analysis set was determined prior to use of allocation 
information. 
The primary outcome, HbA1c 12 months following randomisation,  used least-squares regression 
adjusted for age category and centre as a random effect. Due to the expected low incidence of 
events secondary binary outcomes are presented as unadjusted relative risks. A per protocol analysis 
was undertaken for the primary outcome to check robustness of conclusions to major pre-specified 
protocol deviations (see Table S2). BMI and height were standardised using WHO growth standards  
34,35 and analysed using analysis of covariance with respective baseline measures, age-strata and 
treatment group included as covariates in the model with centre fitted as a random effect.  Insulin 
requirements (units/kg/day) were calculated to reflect insulin use over a 4 week period and were 
then analysed as per growth outcomes without baseline measure reflecting the absence of insulin 
use in this untreated population prior to randomisation. PedsQL overall score (0-100) at 12 months 
was calculated as per PedsQL guidelines according to the age-specific questionnaires used and were 
then analysed as per growth outcomes. Partial remission rate at 12 months (defined as insulin dose 
adjusted HbA1c (IDAAC) < 9) was calculated using HbA1c, weight and daily insulin dose and analysed 
as per binary outcomes. A safety analysis was conducted on AE data according to the method of 
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insulin delivery at the time of the event. The incidence density rate (IDR) was used to quantify the 
number of patients with at least one new case per population at risk in a given time period. The 
denominators are the sum of the person-time in years for each treatment group (accounting for 
treatment switches) of the at risk population.For the cost-utility analysis, UK HUI2 tariffs26  were used 
to estimate utilities and trapezoidal rule to calculate QALYs. Resource use was costed from the 
perspective of the NHS using the National Tariff and other national unit costs. The ratio of the 
differences between intervention groups in costs and QALYs was compared with the NHS cost-
effectiveness threshold of £20,000 per QALY. The joint uncertainty in costs and QALYs was 
considered through 10,000 Bootstrap replicates (bias corrected and accelerated). A lifetime 
modelled extrapolation was only planned if differences were apparent in HbA1c between 
intervention groups at 12-months. 
STUDY FUNDING 
The UK National Institute for Health Research Health Technology Assessment Programme funded 
the study. Roche provided insulin pumps and consumables at a 25% discounted cost. Insulin pumps 
from other manufacturers were also used at the discretion of the treating clinician.   
 
RESULTS 
Internal Pilot 
Recruitment data from the internal pilot study showed acceptable consent rates, no evidence of 
patient selection bias and supported the parameters used in the sample size calculation. The 
oversight committees recommended progression to the full study.  Data from patients recruited to 
the internal pilot study were included in the full study. 
Study Participants 
Between May 2011 and January 2016, 976 patients diagnosed with TID were assessed for eligibility 
in 15 study centres. Of 689 patients who were eligible and approached for consent, 294 (42.7%, 
CSII=144, MDI=149) consented to participate. One patient withdrew before starting their 
14 
 
randomised treatment.  The sample size calculation was inflated to 316 participants to allow for 10% 
attrition, the observed attrition was lower such that the trial was stopped following 294 
randomisations to provide the numbers required to achieve 80% power. (Figure 1). Of patients 
invited to participate in SCIPI that declined to be randomised, 66% (259/395) stated they and/or 
their parent/carer had a strong preference for MDI and 9% (39/395) because they had a strong 
preference for CSII.  
Eighty (91/114) percent of participants and 92% (130/142) of parents/carers randomised to CSII 
received their favoured preferred treatment, compared to 37% (41/112) of participants and 28% 
(42/148) of parents/carers randomised to MDI (p<0.0001).  
Age, gender, ethnicity and deprivation score did not differ between those who consented to 
participate and those who declined (Table S1 supplementary material), or between treatment arms 
(Table 1).   
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Table 1: Baseline characteristics of the participants  
 CSII 
N=144 
MDI 
N=149 
Total 
N=293 
Age at randomisation (years):     
Median (IQR) 9.9 (5.7 to 12.2) 9.4 (5.8 to 12.5) 9.8 (5.7 to 12.3) 
Age category:     
7mths to <5 years: N (%) 33 (22.9) 32 (21.5) 65 (22.2) 
5 to <12 years: N (%) 71 (49.3) 76 (51) 147 (50.2) 
12 to 15 years: N (%) 40 (27.8 41 (27.5) 81 (27.6) 
Gender:     
Female: N (%) 71 (49.3) 69 (46.3) 140 (47.8) 
Male: N (%) 73 (50.7) 80 (53.7) 153 (52.2) 
Ethnicity*: [N missing data] [1] [3] [4] 
Asian or Asian British 3 (2.1%) 3 (2.1%) 6 (2.1%) 
Black or British Black 0 (0%) 3 (2.1%) 3 (1%) 
British White 124 (86.7%) 118 (80.8%) 242 (83.7%) 
Indian 2 (1.4%) 2 (1.4%) 4 (1.4%) 
Mixed 4 (2.8%) 6 (4.1%) 10 (3.5%) 
Other White 6 (4.2%) 8 (5.5%) 14 (4.8%) 
Other 3 (2.1%) 2 (1.4%) 5 (1.7%) 
Pakistani 1 (0.7%) 4 (2.7%) 5 (1.7%) 
Deprivation score continuous*: [N missing [7] [6] [13] 
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data] 
         Median (IQR) 19.4 (8.9 to 
37.9) 
14.7 (7.8 to 
31.8) 
17 (8.4 to 35.8) 
BMI* SDS:  [N missing data] [20] [17] [37] 
Mean (SD) 0.2 (1.3) 0.1 (1.4) 0.1 (1.3) 
Height SDS: [N missing data] [20] [17] [37] 
Mean (SD) 0.3 (1.1) 0.3 (1.1) 0.3 (1.1) 
HbA1c (mmol/mol): [N missing data] [12] [18] [30] 
Mean (SD) 104.6 (24.4) 102.6 (26.7) 103.6 (25.5) 
Blood glucose (mmol/L): [N missing data] [3] [3] [6] 
Mean (SD) 26.8 (9.2) 26.9 (10) 26.9 (9.6) 
Blood pH: [N missing data] [17] [16] [33] 
Mean (SD)  7.3 (0.2) 7.3 (0.1) 7.3 (0.2) 
* Ethnicity was self-reported.  
BMI: Body mass index is the weight in kilograms divided by the square of the height in meters.  
Deprivation Score 0 to 100 with 100 indicating greater deprivation.  
IQR: Inter quartile range, SD: Standard deviation. 
 
 
 
 
 
 
Figure 1: CONSORT diagram illustrating patient flow from diagnosis to completion of the study 
protocol 
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Adherence to the Protocol 
A CONSORT diagram illustrating the pathway of patients from diagnosis to study completion is given 
in Figure 1. Retention and adherence data are reported in Figure S1 and Table S2, supplementary 
material. All participants received their allocated interventions other than one participant who 
withdrew consent immediately following randomisation. Twenty-one of 144 participants (14.6%) 
switched from CSII to MDI, and 30 of 149 participants (20.1%) switched from MDI to CSII.  Primary 
outcome data were available for 97% (285/293) of participants. Primary and secondary outcome 
measures are provided in Table 2. 
 
Table 2: Primary and secondary outcome measures 
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Continuous Outcome Adjusted mean 
CSII 
(95% CI) 
N=144 
Adjusted mean 
MDI 
(95% CI) 
N=149 
Adjusted mean 
difference 
(CSII-MDI), (95% CI) 
p-value 
HbA1c (mmol/mol) at 12 months: 
Intention-To-Treat (ITT)*# 
n=143 
60.9 (58.5 
to63.3) 
n=142 
58.5 (56.1 
to60.9) 
 
2.4 (-0.4 to 5.3) 
 
0.09 
HbA1c (mmol/mol) at 12 months: Per 
Protocol (PP)# 
n=87 
60.2 (56.4 to 
63.9) 
n=66 
59.3 (55.3t o 
63.2) 
 
0.9 (-3.2 to 5.0) 
 
0.67 
Change in BMI SDS*$ n=122 
0.6 (0.8) 
n=122 
0.5 (0.8) 
 
0.1 (0 to 0.3) 
 
0.13 
Change in height SDS*¥ n=122 
-0.1 (0.5) 
n=122 
0 (0.4) 
 
-0.1 (-0.2 to 0) 
 
0.10 
Insulin requirements (units/kg/day)*# n=87 
0.7 (0.2) 
n=64 
0.6 (0.3) 
 
0.1 (0.0 to 0.2) 
 
0.01 
Binary Outcome Number (%) CSII 
N=144 
Number (%) MDI 
N=149 
Relative risk 
(CSII/MDI), 
 (95% CI) 
p-value 
Participants with HbA1c 
<58mmol/mol* 
n=143 
66 (46.2) 
n=142 
78 (54.9) 
 
0.84 (0.67 to 1.06) 
 
0.16 
Participants with HbA1c 
<48mmol/mol* 
n=143 
22 (15.4) 
n=142 
29 (20.4) 
 
0.75 (0.46 to 1.25) 
 
0.28 
Incidence of Severe Hypoglycaemia* n=144 
6 (4.2) 
n=149 
2 (1.3) 
 
3.1 (0.6 to 15.1) 
 
0.17 
Incidence of Diabetic Ketoacidosis* n=144 
2 (1.4) 
n=149 
0 
 
5.2 (0.3 to 106.8) 
 
0.24 
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*Intention to treat analysis. 
# Adjusted for randomisation strata (age category – fixed effects; centre – random effects). 
$ Adjusted for randomisation strata (age category – fixed effects; centre – random effects) and 
baseline BMI SDS. 
¥ Adjusted for randomisation strata (age category – fixed effects; centre – random effects) and 
baseline height SDS. 
BMI: body mass index.  
IDAAC: Insulin dose adjusted HbA1c. 
 
 
Primary Outcome 
The treatment arms were comparable for HbA1c at 12 months with differences between the 
treatment arms being small and unimportant in the ITT analysis (CSII 143, MDI 142), Table 2, (see 
Table S3, supplementary material, for full primary outcome results split by age group)  or the per 
protocol analysis. Sensitivity analyses demonstrated robustness of results to the measurement of 
HbA1c at central laboratory and POC. (Table S4, supplementary material). Details of HbA1c by age 
group and at each time point are given in Figure S2, supplementary material. The study was not 
powered to detect differences in glycaemic control between age groups. However, the observed 
HbA1c values were generally lower for the youngest and oldest age groups during treatment with 
MDI, although there is a lot of uncertainty when comparing across groups . A Forest plot 
demonstrating stability of treatment effect over time is provided (Figure S3, supplementary 
material), despite changes in NHS diabetes care during the SCIPI trial. Forest plots of the primary 
outcome split by subgroup (Figure S4, supplementary material) also show consistency of treatment 
effect across age groups and SCIPI centres.  
The trial was powered to detect a difference between groups in their measures at 12 months 
unadjusted for baseline values. The prognostic value of significance of HbA1c at diagnosis of TID was 
not well recognised at the time SCIPI opened to recruitment.  Two exploratory analyses were 
considered to include HbA1c measured at baseline as a continuous explanatory variable (see Table 
Partial remission (IDAAC<9)* n=86 
21 (24.4) 
n=64 
21 (32.8) 
 
0.74  (0.45 to 1.24) 
 
0.28 
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S5, supplementary material). These results did not alter the SCIPI study conclusions for CSII 
compared with MDI at 12 months [adjusted mean difference between treatment groups (CSII – MDI) 
2.9; 95% CI –0.02 to 5.9], but did suggest the importance of early baseline values for 12-month 
measurements (HbA1c level baseline coefficient estimate 0.07; standard error 0.03; 95% CI 0.01 to 
0.13).  
Another exploratory analysis considered the impact of deprivation (see Table S7, supplementary 
material).  While there was an association of higher baseline HbA1c values and of higher deprivation 
scores being associated with higher HbA1c at 12 months the conclusions remained unaltered: 
adjusted mean difference in HbA1c at 12 months between treatment groups (CSII-MDI) 2.9 
mmol/mol 95% CI (-0.02, 5.9)  and (CSII-MDI) 2.2 mmol/mol 95% CI (-0.7, 5.0) respectively.  
Secondary Outcomes 
Secondary outcomes were analysed as per ITT (Table 2). 
There was no difference in the number of participants achieving HbA1c targets ( <58mmol/mol, the 
target until August 2015, and <48mmol/mol, the target set in August 201528). 
Change in BMI and height SDS were similar between treatment arms.  
Insulin dose data were available for 52% of participants (CSII 87/144, MDI 64/149). Insulin 
requirements were higher in those treated with CSII (0.1 units/kg/day, 95% CI 0.0 to 0.2, p = 0.01), 
primarily in the oldest participants. The basal bolus ratio for patients treated with CSII, across the 
lifetime of the study, was 0.8 starting from 0.73 at 1 month fluctuating up and down throughout the 
course of the trial ending at 0.67 at 12 months. (Figure S5 and Table S6, supplementary data). Similar 
data for MDI are not as robust as they depend on patient reporting.  
Eight episodes of severe hypoglycaemia were reported (CSII=6, MDI=2) and two episodes of DKA 
(CSII=2, MDI=0).   
The safety dataset reports events were categorised according to the treatment the participant was 
receiving at the time of the AE and takes into account temporary or permanent switches in the 
method of insulin delivery. The total number of events experienced and the number of participants 
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experiencing at least one event are provided along with the Incident Density Ratio (IDR), defined as  
the number of patients with at least one new AE per population at risk in a given time period.  
Fifty-four AEs were reported in 36 participants treated with CSII at the time of the AE, 29 of which 
were related to the insulin pump, with IDR of 25.0 participants with at least one event per 100-
person-years. Seventeen AEs were reported in sixteen participants (IDR 10.5 participants) treated 
with MDI at the time of the AE, two of which were related to injection device.  
Fourteen SAEs were reported in nine participants (IDR 6.2 participants) treated with CSII at the time 
of the SAE and 8 SAEs in 8 participants (IDR 5.3 participants) treated with MDI at the time of the SAE. 
Adverse event data are summarised in Table 3.   
Patients randomised to CSII had twice as many TID related Emergency Department visits and 
inpatient stays (122 visits made by 35/144 patients), than those randomised to MDI (60 visits made 
by 25/149 patients); a mean difference of 0.4 per patient (95% CI 0.1 to 0.9). Reasons for those that 
were recorded as SAEs are provided in Table 3. 
 
 
 
 
 
 
 
Table 3: Serious adverse events and adverse events 
  CSII 
144.1 Total 
person years 
144 patients 
MDI 
151.9 Total 
person years 
149 patients 
CSII 
144.1 Total 
person years 
144 patients 
MDI 
151.9 Total 
person years 
149 patients 
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  Adverse Events Serious Adverse Events* 
Category Description Events Patients 
(IDR) 
Events Patients 
(IDR) 
Events Patients 
(IDR) 
Events Patients 
(IDR) 
All Diabetic 
Ketoacidosis 
2 2  (1.4) 0 0 (0) 2 2 (1.4) 0 0 (0) 
Insulin 
administration 
error 
2 2 (1.4) 5 5 (3.3) 2 2 (1.4) 3 3 (2) 
Pump Failure 4 3 (2.1) 0 0 (0) 0 0 (0) 0 0 (0) 
Severe 
Hypoglycaemia 
6 6 (4.2) 2 2 (1.3) 1 1 (0.7) 0 0 (0) 
Site Infections 8 7 (4.9) 0 0 (0) 1 1 (0.7) 0 0 (0) 
other - specify 32 22 
(15.3) 
10 10 (6.6) 8 6 (4.2) 5 5 (3.3) 
Device Diabetic 
Ketoacidosis 
1 1 (0.7) 0 0 (0) 1 1 (0.7) 0 0 (0) 
Pump Failure 4 3 (2.1) 0 0 (0) 0 0 (0) 0 0 (0) 
Severe 
Hypoglycaemia 
2 2 (1.4) 0 0 (0) 0 0 (0) 0 0 (0) 
Site Infections 8 7 (4.9) 0 0 (0) 1 1 (0.7) 0 0 (0) 
other - specify 14 11 (7.6) 3 3 (2) 0 0 (0) 0 0 (0) 
Carer 
error 
Insulin 
administration 
error 
1 1 (0.7) 4 4 (2.6) 0 0 (0) 0 0 (0) 
other - specify 5 2 (1.4) 0 0 (0) 1 1 (0.7) 0 0 (0) 
Meter 
error 
other - specify 3 3 (2.1) 1 1 (0.7) 5 4 (2.8) 2 2 (1.3) 
Incidental 
illness 
Insulin 
administration 
error 
1 1 (0.7) 0 0 (0) 1 1 (0.7) 0 0 (0) 
other - specify 5 5 (3.5) 3 3 (2) 0 0 (0) 1 1 (0.7) 
Other Diabetic 
Ketoacidosis 
1 1 (0.7) 0 0 (0) 1 1 (0.7) 0 0 (0) 
Insulin 
administration 
error 
0 0 (0) 1 1 (0.7) 3 2 (1.4) 3 3 (2) 
Severe 
Hypoglycaemia 
4 4 (2.8) 2 2 (1.3) 1 1 (0.7) 2 2 (1.3) 
other - specify 5 4 (2.8) 3 3 (2) 0 0 (0) 0 0 (0) 
 
Child reported PedsQL (diabetes module) score at 12 months was available for 71% (CSII 104, MDI 
104) but 26 children in each treatment group were too young to complete the questionnaire. 
Adjusted mean difference at 12 months of 3.1 (95% CI -0.6 to 6.8) favoured CSII but the result was 
not statistically significant. Parents of participants (CSII 128/144, MDI 123/149) reported a 
statistically significantly higher score with CSII with adjusted mean difference 4.1 (95% CI 0.6 to 7.6). 
This result should be interpreted against meaningful differences being 5 points or more.36 
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There were 4.3 (95% CI 0.6 to 8.0) more contacts with healthcare professionals per participant 
treated with CSII (21.2), using texts, e-mails and phone calls, than those treated with MDI (16.9).  
Mean total costs were higher by £1,863 (95% CI £1,620 to £2,137) for CSII than for MDI; with the 
majority of this difference (£1,177) due to the additional cost of consumables and device 
(undiscounted annualised cost £600 CSII versus £80 MDI) (Table 4). There was no significant 
difference in QALYs between CSII (0.910) and MDI (0.916) [difference in means of -0.006 QALYs (95% 
CI, -0.031, 0.018)]. The probability of CSII being more expensive and less effective than MDI was 
0.69, with no likelihood of CSII being cost-effective at a threshold of £20,000 per QALY.   
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Table 4: Resource use in participants treated with CSII compared to MDI 
 Cost [mean £ (95% CI)] 
Items of resource use  CSII MDI Difference  
Device (pump* 4-year lifespan or 2 pen 
devices) 
600 (596 to 606) 80 (80 to 80) 520 (516 to 526) 
Consumables* (e.g. needles, infusion 
sets, reservoirs) 
1841 (1826 to 1861) 664 (664 to 664) 1177 (1162 to 1197) 
Insulin (prescribed) 422 (364 to 486) 482 (426 to 541) -60 (-142 to 24) 
Healthcare professional contacts 
(telephone calls, faxes, texts or e-
mails) 
138 (117 to 162) 108 (92 to124) 30 (3 to 59) 
Scheduled outpatients visits 434 (434 to 434) 434 (434 to 434) 0 (0to 0) 
Unscheduled outpatient visits 309 (272 to 346) 328 (292 to 366) -19 (-71to 33) 
Inpatient stays costed from HRGs 387 (245 to 553) 219 (142 to 306) 168 (5to 352) 
Emergency Department visits 26 (16 to 39) 13 (8 to19) 13 (2to 27) 
Other hospital e.g. ward visits 3 (1 to 7) 3 (1 to5) 1 (-3to5) 
Family doctor visits 71 (56 to 88) 57 (45to 69) 15 (-5to 35) 
Home visits 106 (80 to 138) 83 (66to 100) 23 (-9to 59) 
School visits 53 (43 to 64) 56 (44to 69) -3 (-19to 13) 
Concomitant medications 12 (8 to 17) 15 (8 to 23) -2 (-12 to 6) 
Total cost 4404 (4197 to 
4642) 
2541 (2412 to 
2672) 
1863 (1620 to2137) 
* 25% discount not included. 
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DISCUSSION 
Principal findings  
In this RCT of newly diagnosed paediatric TID patients, CSII treatment was neither more clinically 
effective than MDI nor cost-effective by the standards of the NHS. This was consistent across centres 
and strengthens the lack of evidence to support CSII. There is evidence that glycaemic control in the 
first year of diagnosis is predictive of longer term outcomes,37,38 and this is likely to be a critical 
period of care. Partial recovery of insulin production during the first year of diagnosis may 
significantly alter the treatment paradigm compared to later in the course of TID and our findings 
should not be applied beyond the first year of diagnosis.  
Strengths and limitations of study  
Our data are strengthened by a high retention rate and consistency of age, gender, ethnicity and 
deprivation between treatment arms.  Furthermore, age, gender, ethnicity and deprivation did not 
differ between those who consented and those who declined to participate. Participants were 
recruited at diagnosis of TID and core diabetes education and contact with health care professionals 
was balanced across treatment arms.  
Our recruitment rate was lower than predicted and was strongly influenced by early treatment 
preference. The diagnosis of TID has been associated with symptoms of posttraumatic stress 
disorder in parents,39 and for some families it may not have been possible to contemplate 
randomisation to a new treatment so soon after diagnosis. Had we deferred recruitment, we may 
have achieved higher recruitment rates.  At the point of randomisation, those randomised to 
treatment with CSII were significantly more likely to have received their preferred treatment and it is 
likely that we recruited a population of patients favouring CSII. This may explain the higher numbers 
switching from MDI to CSII during follow up. Examination of glycaemic control at the time of 
switching did not indicate poorer control.  Future studies should examine how preference and 
disappointment may influence utilisation of randomised treatments. 
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The ITT analysis included all participants in the group they were randomised to while the per 
protocol analysis excludes participants with major protocol deviations which included switching 
method of delivery. This allows some consideration of the effect, and while both analyses were not 
significant the conclusions are robust. In addition, to account for participants that switched method 
of delivery the safety population analysed participants in the group to the method of insulin delivery 
at the time of the safety event. 
The NPDA report  improvements in glycaemic control from 2010/2011 (72mmol/mol England and 
70mmol/mol in Wales) to 2016/2017 (64mmol/mol, both England and Wales).1 During this period a 
number of national initiatives have been undertaken which are likely to have contributed to this 
sustained improvement. However, only 15% of patients treated with CSII and 20% of patients 
treated with MDI achieved an HbA1c within the target range at the end of the first year of 
treatment. Glycaemic control is poorer in the United Kingdom than in other European countries and 
North America where CSII is used more commonly,11  leading to speculation that increased use of 
CSII  may improve glycaemic control.  The relative inexperience of NHS practitioners in CSII 
treatment could have obscured the potential benefits of this treatment.  However, study sites were 
selected on the availability of a core set of trained and experienced staff. There was no evidence of a 
treatment effect over time, and block randomisation ensured balance between treatment arms.  
The development,validation, documentation and monitoring of an education package and treatment 
protocols would have strengthened the study.  However, in the absence of robust evidence to 
inform the development of these protocols, this would have incurred significant additional cost and 
delays.  Standardisation of educational packages is ideal, but it is important that these can be 
individualised to meet the needs of patients and their families. The pace at which education can be 
delivered to an unselected cohort of newly diagnosed patients will be more measured than 
education of selected patients experienced in the treatment of TID, and it may be unrealistic to 
expect all families to achieve a high level of sophistication in CSII use. Additional education in the use 
of CSII may have reduced the prevalence of AEs in this arm and improved glycaemic control, 
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although this should be set in the context of the adult study, INPUT, which reported no effect of a 
structure education programme on glycaemic control in patients treated with CSII .40 
A large number of adverse events were reported in the study cohort, and this is consistent with the 
background population of patients with childhood TID treated with CSII. The NPDA report that 
treatment with CSII increased the risk of being admitted to hospital in DKA by 23%, and of being 
admitted to hospital for reasons other than DKA or hypoglycaemia by 27%. CSII treatment did not 
confer benefit or increased risk from admission with hypoglycaemia.41  
The speed of technological developments outpaces the time required to deliver a clinical trial. It may 
be argued that the findings of the SCIPI trial are outdated: Technology has advanced, clinical teams 
have greater experience of CSII, and improved education programmes and psychological support 
equips patients and their families to manage this therapy more successfully with fewer adverse 
events. However, observational data from the most mature CSII services report benefits in HbA1c 
below thresholds felt to be clinically meaningful, 9,13 taking no account of the effect of deprivation or 
ethnicity on clinical outcomes. Enhanced education and psychological support also has the potential 
to improve quality of life and clinical outcomes in patients treated with MDI.  To improve the 
timeframes required to deliver the evidence development of a clinical trial platform should be 
considered. 
 
Comparison with other studies  
Our findings are consistent with those reported in a smaller RCT of newly diagnosed patients,9 and 
previous studies of patients with established TID. 10, 42-44 Authors of a systematic review of adult and 
paediatric patients  concluded that CSII enabled superior glycaemic control and QoL than MDI with 
fewer episodes of hypoglycaemia, but cautioned that the inclusion of observational data may have 
introduced bias.45 
The reported effect of CSII on QoL and treatment satisfaction varies. 10, 40-42 In our study, parents of 
participants treated with CSII reported a small, but significantly higher PedsQL score for the QoL of 
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their children.  A qualitative approach may detect differences in QoL that were not identified in our 
questionnaire-based approach. No adjustments for multiplicity were applied to secondary outcomes 
and SCIPI was not powered to detect differences within these outcomes. Consequently, the results 
should not be judged solely by the presence or absence of statistical significance. 
Tools for recording insulin use were less robust in those treated with MDI than CSII, and difficulties 
with data downloads from glucometers and pumps, and missing data in handheld records resulted in 
a large number of missing data. In contrast to previous studies,13,18,20 insulin requirements were 
higher in patients treated with CSII.  This may reflect a reduction in the intensity of MDI treatment as 
older participants gain independence, or under reporting. Recognising this uncertainty, our data 
relating to partial remission should be interpreted with caution.   
Conclusions and policy implications  
Many patient advocacy groups and health care professionals are of the strong opinion that 
treatment with CSII is beneficial and further research should focus on determining what these 
perceived benefits are and to develop validated tools to measure them. Individual patients are likely 
to experience benefits from this treatment that are not directly associated with the outcomes 
measured in this study. For example, the preschool child who consumes carbohydrates and exercises 
erratically may benefit from a treatment with fewer injections and a basal insulin profile that can be 
modified readily.  For the SCIPI cohort, longer term observation is required to assess how treatment 
in the first year has influenced the trajectory of glycaemic control in future years.  
Evolving technology that automates glucose monitoring and insulin dose adjustment has the 
potential to reduce the burden of CSII therapy to patients and families, and enable superior 
glycaemic control to that reported in SCIPI participants. These technologies are likely to be 
considerably more expensive than those evaluated in this study and evidence should be sought to 
support their use. 
In considering the outcomes of the SCIPI study it is important to recognise the following points (1) 
glycaemic control was suboptimal in both treatment arms (2) patients recruited to the study were 
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newly diagnosed and more favourable results may be achieved with CSII in patients more 
experienced in the treatment of TID (3) advances in technology may reduce the burden of CSII 
therapy, and facilitate superior control in time.  
In resource limited settings, it is important that the introduction of novel, expensive therapies is 
informed by robust clinical data demonstrating superiority. Data from the SCIPI study demonstrate 
that the use of CSII was neither clinically beneficial nor cost effective in the first year of TID, and 
resources may be more effectively invested in other measures to improve glycaemic control.  
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